Dergiler / Journal of Emergency Medicine Case Reports / 2018 / Cilt: 9 - Sayı: 1

Methimazole-Induced Febrile Neutropenia

Sayfa
13–15
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

A major fatal adverse effect of ATDs, if unrecognized and not treated on time,is agranulocytosis, which is defined as an absolute neutrophil count of

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Introduction: Antithyroid drugs (ATD) are commonly used for the treatment of thyrotoxicosis, particularly for the treatment ofGrave’s disease.
📊
Temel Bulgular & Veri:Methimazole is the first line ATD.
💡
Sonuç & Katkı:A major fatal adverse effect of ATDs, if unrecognized and not treated on time,is agranulocytosis, which is defined as an absolute neutrophil count of
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Introduction: Antithyroid drugs (ATD) are commonly used for the treatment of thyrotoxicosis, particularly for the treatment ofGrave’s disease. Methimazole is the first line ATD. A major fatal adverse effect of ATDs, if unrecognized and not treated on time,is agranulocytosis, which is defined as an absolute neutrophil count of

🔖

Bu Makaleye Atıf Yap

VARIŞLI, B., YILDIRIM, S., PAKER, Ş., KARAÇAM, H. (2022). Methimazole-Induced Febrile Neutropenia. Journal of Emergency Medicine Case Reports, Cilt: 9 - Sayı: 1, 13–15. https://ajindex.com/articles/562632

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Melmed S, Polonsky KS, P. Larsen R, Kronenberg HM. Williams textbook of endocrinology. 13th edition. ed. Hyperthyroid Disorders, ed. T.F. Davies, P. Laurberg, and R.S. Bahn. 2016, Philadelphia, PA: Elsevier. xviii, 1916 pages
  2. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016; 27(suppl 5): p. v111-v8. [CrossRef ] 3. Weetman AP. The thyroid gland and disorders of thyroid function: Oxford Textbook of Medicine. Oxford University Press; 2010: 1826-44. [CrossRef] 4. Vicente N, Cardoso L, Barros L, Carrilho F. Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management. Drugs R D 2017; 17: 91-6. [CrossRef ] 5. Yang J, Zhong J, Xiao XH, Zhou LZ, Chen YJ, Liu JH, et al. The relationship between bone marrow characteristics and the clinical prognosis of antithyroid drug-induced agranulocytosis. Endocr J 2013; 60: 185-9. [CrossRef ] 6. Cheung CL, Sing CW, Tang CS, Cheng VK, Pirmohamed M, Choi CH, et al. HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis. Clin Pharmacol Ther 2016; 99: 555-61. [CrossRef ] 7. Hallberg P, Eriksson N, Ibañez L, Bondon-Guitton E, Kreutz R, Carvajal A, et al. Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes Endocrinol 2016; 4: 507-16. [CrossRef ] 8. Jabr FI. Methimazole-induced severe febrile neutropenia responding to recombinant human granulocyte colony stimulating factor. South Med J 2008; 101: 665. [CrossRef ]